Importer of Controlled Substances, Notice of Application; Watson Pharma, Inc., 33440 [2013-13177]
Download as PDF
<![CDATA[
33440
Federal Register / Vol. 78, No. 107 / Tuesday, June 4, 2013 / Notices
Paul Madison Eckles, Skadden, Arps,
Slate, Meagher & Flom, Four Times
Square, 42nd Floor, New York, NY
10036, (212) 735–2578,
pmeckles@skadden.com.
For Simon & Schuster:
Yehudah Lev Buchweitz, Weil, Gotshal
& Manges LLP (NYC), 767 Fifth Avenue,
25th Fl., New York, NY 10153, (212)
310–8000 x8256,
yehudah.buchweitz@weil.com.
Additionally, courtesy copies of this
Response to Comments have been
provided to the following:
For the State of Connecticut:
W. Joseph Nielsen, Assistant Attorney
General, Antitrust Division, Office of the
Attorney General, 55 Elm Street,
Hartford, CT 06106, (860) 808–5040,
Joseph.Nielsen@ct.gov.
For the State of Texas:
Gabriel R. Gervey, Assistant Attorney
General, Antitrust Division, Office of the
Attorney General of Texas, 300 W. 15th
Street, Austin, Texas 78701, (512) 463–
1262, gabriel.gervey@oag.state.tx.us.
For the Private Plaintiffs:
Jeff D. Friedman, Hagens Berman, 715
Hearst Ave., Suite 202, Berkeley, CA
94710, (510) 725–3000,
jefff@hbsslaw.com.
s/Stephen T. Fairchild
Stephen T. Fairchild
Attorney for the United States, United States
Department of Justice, Antitrust Division, 450
Fifth Street NW., Suite 4000, Washington, DC
20530, (202) 532–4925,
stephen.fairchild@usdoj.gov.
[FR Doc. 2013–13133 Filed 6–3–13; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
tkelley on DSK3SPTVN1PROD with NOTICES
Importer of Controlled Substances,
Notice of Application; Watson Pharma,
Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on May 3, 2013, Watson Pharma,
Inc., 2455 Wardlow Road, Corona,
California 92880–2882, made
application by renewal to the Drug
Enforcement Administration (DEA) for
registration as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
VerDate Mar<15>2010
18:33 Jun 03, 2013
The company plans to import the
listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
FDA approved or non-approved dosage
form for commercial distribution in the
United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C. 952
(a)(2)(B) may, in the circumstances set
forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 5, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 24, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–13177 Filed 6–3–13; 8:45 am]
BILLING CODE 4410–09–P
II
II
II
II
Jkt 229001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Registration; Rhodes
Technologies
By a Notice dated April 10, 2013, and
published in the Federal Register on
April 19, 2013, 78 FR 23594, Rhodes
Technologies, 498 Washington Street,
Coventry, Rhode Island 02816, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Opium Raw (9600) .......................
Poppy Straw Concentrate (9670)
Schedule
II
II
The company plans to import the
listed controlled substances in order to
bulk manufacture controlled substances
in Active Pharmaceutical Ingredient
(API) form. The company distributes the
manufactured API’s in bulk to its
customers.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a), and
determined that the registration of
Rhodes Technologies to import the basic
classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Rhodes Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: May 24, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–13178 Filed 6–3–13; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00116
Fmt 4703
Sfmt 9990
E:\FR\FM\04JNN1.SGM
04JNN1
]]>Agencies
[Federal Register Volume 78, Number 107 (Tuesday, June 4, 2013)]
[Notices]
[Page 33440]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-13177]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances, Notice of Application; Watson
Pharma, Inc.
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on May 3, 2013, Watson Pharma, Inc., 2455 Wardlow Road,
Corona, California 92880-2882, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic classes of controlled
substances will be granted only for analytical testing and clinical
trials. This authorization does not extend to the import of a finished
FDA approved or non-approved dosage form for commercial distribution in
the United States.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedules I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 5, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: May 24, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-13177 Filed 6-3-13; 8:45 am]
BILLING CODE 4410-09-P
